$CDXS

CODEXIS, INC. (CDXS): Submission of Matters to a Vote of Security Holders

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001200375 0001200375 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,

Original reporting
Published Jun 22, 2026, 10:02 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 10:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$CDXS
Neutral
high confidence
Mentioned
$CDXS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDXSNeutralLow
01

Why it matters

This is primarily a compliance disclosure of voting outcomes: directors elected, KPMG LLP ratified as independent auditor for 2026, and an advisory say-on-pay vote approved.

02

Market read

While it confirms governance decisions, the filing does not introduce new operating, financial, or regulatory catalysts.

03

What to watch

Traders may instead focus on any concurrent proxy items (not included here) such as strategic proposals, compensation changes, or director background shifts.

Relevance 6/10Novelty 2/10Timing: post-annual-meeting 8-K filed June 22, 2026

Background

The company filed an SEC Form 8-K for Item 5.07, summarizing final results from its June 17, 2026 annual meeting.

Company-level read

Ticker impact

$CDXSNeutralHigh confidence
Context

Codexis reported final 2026 annual meeting vote results, including director elections, KPMG ratification, and an advisory say-on-pay outcome.

Expected impact

Low likelihood of a sustained price move solely from these vote tallies.

Evidence & confidence

The filing discloses standard proxy voting results (board election, auditor ratification, non-binding executive comp vote) without new financial guidance, transactions, or enforcement actions.

Market effects

No clear sector read-through; governance vote mechanics only.

No material regional impact indicated.

No global relevance beyond company-specific corporate governance.

Counterpoint

If vote results were unusually contentious, it could hint at shareholder dissatisfaction, but the article provides no context (e.g., activism, dissent narrative) to trade on.

Key entities

  • Codexis, Inc.

    Subject of the 8-K; reported final shareholder vote results for directors, auditor ratification, and advisory executive compensation.

  • KPMG LLP

    Ratified by shareholders as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$CDXSMedAI 8/10

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl

$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma

$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

$ELVRMed

Elevra Lithium Ltd (ASX:ELV) Corporate Presentation - Outlines Growth Strategy for North American Lithium Platform

Elevra Lithium Ltd (ASX:ELV) outlined its growth strategy for North American Lithium (NAL) in Quebec, targeting 373,000 tonnes of spodumene concentrate annually. FY26 production was 197,967 tonnes, with revenue of US$202 million. The company plans a three-stage expansion, with initial capital expenditure of US$271 million. FY27 production guidance is 198,000 to 210,000 tonnes.

$CVXMedAI 8/10

Chevron (CVX) Doubles Down on Venezuela with a $7 Billion Oil Bet

Chevron (CVX) plans to invest $7 billion in Venezuela over five years to double oil production to 600,000 barrels per day, adding areas in the Orinoco Belt to its joint venture with PDVSA. The move leverages Chevron's existing presence and aims for low-cost growth, despite political and regulatory risks. Venezuela holds the world's largest crude oil reserves but faces infrastructure challenges.